One of these monoclonals, aβComAb IgMκ GW-23B7, in a passive immunization preclinical trial in old 3xTg-AD mice consisting of seven injections over a 2-month period was able to reverse cognitive deficits in old mice, as well as reduce Aβ and tau oligomers levels [27]. Here, MAPT is linked to Alzheimer disease.